Sidney Kimmel Comprehensive Cancer Center Johns Hopkins

Baltimore, MD, United States

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins

Baltimore, MD, United States
SEARCH FILTERS
Time filter
Source Type

Tsao A.S.,University of Texas M. D. Anderson Cancer Center | Scagliotti G.V.,University of Turin | Bunn P.A.,Aurora University | Carbone D.P.,Ohio State University | And 34 more authors.
Journal of Thoracic Oncology | Year: 2016

Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a "role model" for precision cancer medicine, with several important therapeutic breakthroughs occurring during 2015. These advances have occurred primarily in the immunotherapy field and in treatments directed against tumors harboring specific oncogenic drivers. Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for patients with lung cancer who have advanced disease have occurred. The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of lung cancer during the past year. © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.


Clark P.E.,Vanderbilt Ingram Cancer Center | Agarwal N.,University of Utah | Biagioli M.C.,Vanderbilt Ingram Cancer Center | Eisenberger M.A.,Sidney Kimmel Comprehensive Cancer Center Johns Hopkins | And 23 more authors.
JNCCN Journal of the National Comprehensive Cancer Network | Year: 2013

Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non-muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. Copyright © 2013 by the National Comprehensive Cancer Network. All rights reserved.


Hussain M.,University of Michigan | Carducci M.A.,Sidney Kimmel Comprehensive Cancer Center Johns Hopkins | Slovin S.,Sloan Kettering Cancer Center | Cetnar J.,University of Wisconsin - Madison | And 8 more authors.
Investigational New Drugs | Year: 2014

Summary: Androgen receptor-mediated transcription is directly coupled with the induction of DNA damage, and castration-resistant tumor cells exhibit increased activity of poly (ADP-ribose) polymerase (PARP)-1, a DNA repair enzyme. This study assessed the efficacy and safety of low dose oral PARP inhibitor veliparib (ABT-888) and temozolomide (TMZ) in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) in a single-arm, open-label, pilot study. Patients with mCRPC progressing on at least one docetaxel-based therapy and prostate specific antigen (PSA) ≥ 2 ng/mL were treated with veliparib 40 mg twice daily on days 1-7 and TMZ once daily (150 mg/m2/day cycle 1; if well tolerated then 200 mg/m2/day cycle 2 onwards) on days 1-5 q28 days. Patients received 2 (median) treatment cycles (range, 1-9). The primary endpoint was confirmed PSA response rate (decline ≥ 30 %). Twenty-six eligible patients were enrolled, 25 evaluable for PSA response. Median baseline PSA was 170 ng/mL. Two patients had a confirmed PSA response (8.0 %; 95 % CI: 1.0-26.0), 13 stable PSA, and 10 PSA progression. The median progression-free survival was 9 weeks (95 % CI: 7.9-17) and median overall survival 39.6 weeks (95 % CI: 26.6-not estimable). The most frequent treatment-emergent adverse events (AEs) were thrombocytopenia (77 %), anemia (69 %), fatigue (50 %), neutropenia (42 %), nausea (38 %), and constipation (23 %). Grade 3/4 AEs occurring in > 10 % of patients were thrombocytopenia (23 %) and anemia (15 %). Veliparib and TMZ combination was well tolerated but with modest activity. Biomarker analysis supported the proof of concept that this combination has some antitumor activity in mCRPC. © 2014 Springer Science+Business Media New York.

Loading Sidney Kimmel Comprehensive Cancer Center Johns Hopkins collaborators
Loading Sidney Kimmel Comprehensive Cancer Center Johns Hopkins collaborators